

## References

### I-228

1. Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: A single-arm, open-label, phase 2 basket trial. *Lancet*. 2020;21(5):645-654.
2. Kauffmann-Guerrero D, Huber RM. Orphan drugs in development for the treatment of small-cell lung cancer: Emerging data on lurbinectedin. *Lung Cancer*. 2020;11:27-31.
3. Farago AF, Drapkin BJ, Lopez-Vilarino de Ramos JA, et al. ATLANTIS: A phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. *Future Oncol*. 2019;15(3):231-239.
4. Subbiah, V, Paz-Ares, L, Besse, B, et al. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. *Lung Cancer*. 2020;150:90-6.
5. Zepzelca (lurbinectedin) for injection, for intravenous use [package insert]. Jazz Pharmaceuticals, Inc. Palo Alto, CA. Revised 10/2021.
6. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Lurbinectedin. 2021.
7. National Comprehensive Cancer Network (NCCN). Lurbinectedin. NCCN Drugs and Biologics Compendium®. 2021.
8. Micromedex®Solutions Compendia. 2021.Lurbinectedin.
9. Lurbinectedin In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated July 27, 2020.